Antinociceptive effect of N-(3-(phenylselanyl)prop-2-yn-1-yl)benzamide in mice: Involvement of 5-HT1A and 5-HT2A/2C receptors

Ledebuhr, Kauane Nayara Bahr; Nunes, Gustavo D’Avila; Besckow, Evelyn Mianes; Giehl, Maira Regina; Godoi, Benhur; Bortolatto, Cristiani F.; Brüning, César Augusto

doi:10.1016/j.cbi.2022.109918

Cited by 4 publications

(2 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preclinical studies have explored the effects of organoselenium compounds, particularly their antioxidant [ 66 ], anti-inflammatory, and antinociceptive properties [ 67 , 68 , 69 , 70 ]. However, our research adds value by elucidating the specific advantages and contributions of our approach to the seleno–coumarin compound.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, the data presented align with prior studies indicating that organoselenium compounds and coumarin derivatives can modulate a diverse array of signaling pathways, particularly those associated with supraspinal responses. This suggests that free 4-PSCO and its encapsulated form potentially act as centrally acting analgesics [ 67 , 96 , 103 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

4-(Phenylselanyl)-2H-chromen-2-one-Loaded Nanocapsule Suspension—A Promising Breakthrough in Pain Management: Comprehensive Molecular Docking, Formulation Design, and Toxicological and Pharmacological Assessments in Mice

da Fonseca,

Prado,

Paltian

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Therapies for the treatment of pain and inflammation continue to pose a global challenge, emphasizing the significant impact of pain on patients’ quality of life. Therefore, this study aimed to investigate the effects of 4-(Phenylselanyl)-2H-chromen-2-one (4-PSCO) on pain-associated proteins through computational molecular docking tests. A new pharmaceutical formulation based on polymeric nanocapsules was developed and characterized. The potential toxicity of 4-PSCO was assessed using Caenorhabditis elegans and Swiss mice, and its pharmacological actions through acute nociception and inflammation tests were also assessed. Our results demonstrated that 4-PSCO, in its free form, exhibited high affinity for the selected receptors, including p38 MAP kinase, peptidyl arginine deiminase type 4, phosphoinositide 3-kinase, Janus kinase 2, toll-like receptor 4, and nuclear factor-kappa β. Both free and nanoencapsulated 4-PSCO showed no toxicity in nematodes and mice. Parameters related to oxidative stress and plasma markers showed no significant change. Both treatments demonstrated antinociceptive and anti-edematogenic effects in the glutamate and hot plate tests. The nanoencapsulated form exhibited a more prolonged effect, reducing mechanical hypersensitivity in an inflammatory pain model. These findings underscore the promising potential of 4-PSCO as an alternative for the development of more effective and safer drugs for the treatment of pain and inflammation.

show abstract